Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2 3Phase 1 3Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 245Carcinoma, Non-Small-Cell Lung 226Prostatic Neoplasms 115Neoplasms 106Multiple Myeloma 91Neoplasm Metastasis 77Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 67Ovarian Neoplasms 62Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 48Melanoma 46Leukemia, Lymphocytic, Chronic, B-Cell 44Carcinoma, Renal Cell 43Stomach Neoplasms 42Urinary Bladder Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Triple Negative Breast Neoplasms 40Brain Neoplasms 40Recurrence 39Myasthenia Gravis 38Small Cell Lung Carcinoma 36Lymphoma, Follicular 35Nasopharyngeal Carcinoma 34Head and Neck Neoplasms 34Pancreatic Neoplasms 32Rectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 30Colonic Neoplasms 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Autoimmune Diseases × 1 year × Clear all
NCT07039916 2026-06-15

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Immunovant Sciences GmbH

Phase 3 Recruiting
231 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡